ClinicalTrials.gg
CompletedNCT03345342Updated Apr 29, 2025Results posted

A Study of Paliperidone Palmitate 6-Month Formulation

A Phase 3 interventional study of PP6M and PP3M 350 mg eq. in Schizophrenia, sponsored by Janssen Research & Development, LLC. Completed at 138 sites in 21 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
841
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
6th of 115
841 · median 178
Started
2017
with 1 other
Phase 3
41 of 115
none open now
Registered
99th of 115
by date
Lead sponsor
12 of 115
Janssen Research & Development, LLC

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 6th largest by enrollment, is one of 2 that started in 2017, is one of 41 in phase 3, and was the 99th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate that injection cycles consisting of a single administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2 sequentially administered injections of paliperidone palmitate 3-month PP3M) (350 or 525 mg eq.) for the prevention of relapse in participants with schizophrenia previously stabilized on corresponding doses of paliperidone palmitate 1-month (PP1M) (100 or 150 mg eq.) or PP3M (350 or 525 mg eq.).

Read the detailed description

The primary hypothesis of this study is that the efficacy of PP6M is non-inferior to PP3M for preventing relapse in participants with schizophrenia who were previously stabilized on corresponding doses of PP1M or PP3M. The study consists of mainly 3 phases: a screening phase (up to 28 days), a maintenance phase (of 1 or 3 months), and a double-blind phase (of 12 months [neither the researchers nor the participants know what treatment the participant is receiving]). Additional/conditional phases include a transition phase (before maintenance phase). Study evaluations include efficacy, pharmacokinetics, pharmacodynamics, and safety. The study duration will vary from approximately 13 months to 19 months.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must meet the diagnostic criteria for schizophrenia according to , Fifth Edition (DSM 5) for at least 6 months before screening
  • Must be receiving treatment with paliperidone palmitate (as either the paliperidone palmitate 1-month (PP1M) or paliperidone palmitate 3-month (PP3M) formulation), or injectable risperidone, or any oral antipsychotic
  • Must be able, in the opinion of the investigator, to discontinue any antipsychotic medication other than PP1M) or PP3M during the Screening Phase
  • Must have a full Positive and Negative Syndrome Scale (PANSS) score of less than (\<) 70 points at screening
  • Must have a (BMI) between 17 and 40 kilogram (kg)/meter (m)\^2 (inclusive) and must have a body weight of at least 47 kg at screening
  • Must be willing to receive gluteal injections of medication during the Double-blind Phase

Exclusion criteria

Exclusion Criteria

  • Must not be receiving any form of involuntary treatment, such as involuntary psychiatric hospitalization, parole-mandated treatment, or court-mandated treatment
  • Must not have attempted suicide within 12 months before screening and must not be at imminent risk of suicide or violent behavior, as clinically assessed by the investigator at the time of screening
  • Must not have a diagnosis of moderate or severe substance use disorder (except for nicotine and caffeine) within 6 months of screening; however, acute or intermittent substance use prior to screening is not exclusionary, depending upon the clinical judgment of the investigator
  • Must not have a history of neuroleptic malignant syndrome or tardive dyskinesia
  • Must not have a history of intolerability or severe reactions to moderate or higher doses of antipsychotic medications and must not have any other factors that would, in the judgment of the investigator, indicate that treatment with moderate or higher doses of paliperidone palmitate would be intolerable or unsafe
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
841 participants (actual)

Study arms

  • Experimental
    PP1M: Transition Phase

    Participants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase.

    Drug: PP1M

  • Experimental
    PP1M/PP3M: Maintenance Phase

    All the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase.

    Drug: PP3M 350 mg eq. · Drug: PP3M 525 mg eq. · Drug: PP1M

  • Experimental
    PP6M or Placebo: Double-Blind Phase

    Participants will receive intramuscular injection of PP6M in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274.

    Drug: PP6M · Other: Placebo

  • Experimental
    PP3M: Double-Blind Phase

    Participants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183.

    Drug: PP3M 350 mg eq. · Drug: PP3M 525 mg eq.

Interventions

  • DrugPP6M

    Participants will receive intramuscular injection of PP6M.

    Also known as: R092670

  • Participants will receive intramuscular injection of PP3M 350 mg eq.

    Also known as: R092670

  • Participants will receive intramuscular injection of PP3M 525 mg eq.

    Also known as: R092670

  • DrugPP1M

    Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.

    Also known as: R092670

  • OtherPlacebo

    Participants will receive matching placebo.

06

What researchers measure

Primary outcomes

  1. Time to Relapse During the Double-Blind (DB) Phase

    Time to relapse is time between participant randomization in DB Phase and first documentation of relapse event by end of Month 12 of DB phase. Relapse is defined as: a) Psychiatric hospitalization; b) Positive and Negative Syndrome Scale (PANSS) total score: Increase of 25 percentage (%), 10 point increase in PANSS for 2 analysis separated by 3-7 days if score was greater than (\>) 40, less than or equal to (\<=)40; c) Participants inflicted knowing self-injury/shown violent behavior leading to suicide, clinically significant injury to him/herself or other person/property; d) Participants had suicidal/homicidal ideation/violent behavior that was clinically significant as per investigator; e) PANSS items P1- delusions, P2- conceptual disorganization, P3-hallucinatory behavior, P6- suspiciousness/ persecution, P7-hostility, G8-uncooperativeness: score: greater than or equal to (\>=)5, \>=6 for 2 analysis separated by 3-7 days on any items if maximum score for PANSS: \<=3 or 4, respectively.

    Time frame: Up to 12 months of DB Phase

Secondary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score

    The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and scores for 3 subscales: the 7-item positive-symptom (P) subscale, the 7-item negative-symptom (N) subscale, and the 16-item general-psychopathology symptom (G) subscale. Each item is rated on a scale from 1 (absent) to 7 (extreme). The PANSS total score ranges from 30 (absent disease)-210 (more severe neuropsychiatric symptoms of schizophrenia).

    Time frame: Baseline (DB) to 12 Months of DB Phase

  2. Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score

    CGI-S is defined as clinician-rated scale that assesses the severity of mental illness on a scale of 0 to 7. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to:1: normal, not at all ill; 2: borderline mentally ill; 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. A higher score implies a more severe condition.

    Time frame: Baseline (DB) to 12 Months of DB Phase

  3. Change From Baseline in the Personal and Social Performance (PSP) Scale Total Score

    The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: 1) socially useful activities, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior. Each domain was assessed on a 6-point scale, from 1 (absent) to 6 (very severe) (1 = absent, 2 = mild, 3 = manifest, 4 = marked, 5 = severe, and 6 = very severe). PSP total score was calculated as sum of all the domain scores and ranges from 1 to 100. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision. Higher score indicates better performance.

    Time frame: Baseline (DB) to 12 Months of DB Phase

  4. Percentage of Participants With Symptomatic Remission Based on PANSS Score During DB Phase

    Symptomatic remission was defined as achieving intensity level of mild or moderate on PANSS scale by all 8 items as the determinants for symptomatic remission: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, lack of spontaneity. The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent), 2 (minimal), 3 (mild), 4 (moderate), 5 (moderately severe), 6 (severe) and 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity.

    Time frame: Up to 12 months of DB Phase

  5. Change From Baseline in the Satisfaction With Participants in Social Roles (SPSR) Score

    The SPSR Short Form 8a is a participant-reported outcome used to assess the satisfaction with participation in social roles. The participants were asked to rate 8 items on 5-point Likert scale, with scores ranging from 8 to 40, where higher scores represents higher satisfaction.

    Time frame: Baseline (DB) to 12 Months of DB Phase

  6. Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score

    TSQM-9 consists of 9 questions to assess patients' satisfaction with medication using a range of responses from 1 (extremely dissatisfied) to (7 extremely satisfied). This patient reported outcome provides scores on three parts: effectiveness, convenience, and global satisfaction. The sum of the 9-questions were calculated and used for analysis. The total score ranges from 0 to 63, with higher scores indicating better treatment satisfaction.

    Time frame: Baseline (DB) to 12 Months of DB Phase

  7. Change From Baseline in the Simpson-Angus Rating Scale (SAS) Total Score

    The SAS rates 10 items for general extrapyramidal symptoms (EPS) on a 5-point scale from 0 (normal) to 4 (extreme), including gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head rotation, Glabellar tap, tremor, and salivation. The SAS total score is the average score (total sum of item scores divided by the number of items) and ranges between 0 and 4. Negative change in score indicates improvement. Higher scores denote more severe condition of EPS.

    Time frame: Baseline (DB) to 12 Months of DB Phase

  8. Number of Participants With Symptoms of Akathisia Assessed Using Barnes Akathisia Rating Scale (BARS) Score

    BARS is used to rate observable, restless movements of drug induced akathisia and subjective awareness of restlessness and any distress associated with the akathisia. BARS consists of the following 4 items: objective assessment of akathisia symptoms, subjective assessment of the participants's awareness of inner restlessness, distress restlessness, and global clinical assessment of akathisia. First three items are rated on a 4-point scale ranging from 0 (no abnormal movements or absence of inner restlessness or no distress) to 3 (severe akathisia or awareness of intense compulsion to move most of the time or severe distress). The last item, the global clinical assessment of akathisia, is rated on a 6-point scale, ranging from 0 (no evidence of akathisia) to 5 (severe akathisia).

    Time frame: Up to 12 Months of DB Phase

  9. Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Total Score

    AIMS is a 14-item scale. Items 1 to 8 are rated on a 5-point scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Item 9 assesses the participant's incapacitation due to abnormal movements, and item 10 assesses the participant's awareness of the abnormal movements and associated distress. Items 9 and 10 are rated on 5-point scales ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Items 11 to 14 are yes/no questions regarding the global judgement and dental status of the participant. The total score is the sum of the scores for the 14 items and the possible total score ranges from 0 to 44. A higher total score is indicative of more severe dyskinetic movements.

    Time frame: Baseline (DB) to 12 Months of DB Phase

  10. Number of Participants Based on Columbia Suicide Severity Rating Scale (C-SSRS) Total Score

    The C-SSRS is a questionnaire used for suicide risk assessment. Affirmative or negative responses are provided to items 1 to 5 for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods \[not plan\] without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and items 6 to 10 for suicide behavior (6. Preparatory acts or behavior, 7. Aborted attempt, 8. Interrupted attempt, 9. Actual attempt, 10. Completed suicide). Total score ranges from 1 to 10. Higher scores indicate more severe suicidal ideation.

    Time frame: Baseline and endpoint (12 Months of DB Phase)

  11. Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values During DB Phase

    Number of participants with treatment-emergent abnormal ECG values were reported. It includes heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute (bpm) , abnormally high refers greater than or equal to \[\>=\] 100 bpm), pulse rate (PR) interval (abnormally high refers to \>= 210 milliseconds \[msec\]), QRS interval (abnormally Low refers to \<= 50, abnormally high refers to \>= 120 msec) and QT interval (abnormally low refers to \<= 200, abnormally high \>= 500 msec).

    Time frame: Baseline (DB) to 12 Months of DB Phase

  12. Change From Baseline in the Body Mass Index (BMI) During DB Phase

    Change from baseline in BMI was reported.

    Time frame: Baseline (DB) to 12 Months of DB Phase

  13. Change From Baseline in the Waist Circumference During DB Phase

    Change from baseline in waist circumference was reported.

    Time frame: Baseline (DB) to 12 Months of DB Phase

  14. Change From Baseline in the Body Weight During DB Phase

    Change from baseline in body weight was reported.

    Time frame: Baseline (DB) to 12 Months of DB Phase

  15. Change From Baseline in the Vital Signs (Pulse Rate) During DB Phase

    Change from baseline vital signs (pulse rate) were reported. This included supine pulse rate, standing pulse rate and supine-standing pulse rate.

    Time frame: Baseline (DB) to 12 Months of DB Phase

  16. Change From Baseline in the Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) During DB Phase

    Change from baseline in vital signs including SBP and DBP (supine/standing) were reported.

    Time frame: Baseline (DB) to 12 Months of DB Phase

  17. Change From Baseline in Positive and Syndrome Scale (PANSS) Subscales Score During DB Phase

    The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).

    Time frame: Baseline (DB) to 12 Months of DB Phase

  18. Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Chemistry During DB Phase

    Number of participants with clinically significant abnormal laboratory values in chemistry included alanine aminotransferase (Unit per Litre \[U/L\]), albumin (Gram per Litre \[g/L\]), alkaline phosphatase (U/L), aspartate aminotransferase (U/L), bicarbonate (millimoles per litre \[mmol/L\]), bilirubin (micromoles per litre \[umol/L\]), calcium (mmol/L), chloride (mmol/L), cholesterol (mmol/L), creatinine (umol/L), gamma glutamyl transferase (GGT) (U/L), glucose (mmol/L), high-density lipoproteins (HDL) cholesterol (mmol/L), low density lipoproteins (LDL) cholesterol (mmol/L), lactate dehydrogenase (U/L), phosphate (mmol/L), potassium (mmol/L), protein (mmol/L), sodium (mmol/L), triglycerides (mmol/L), urate (umol/L), urea nitrogen (mmol/L) were reported. Here, ABL signifies abnormally low and ABH signifies abnormally high levels.

    Time frame: Up to 12 Months of DB Phase

  19. Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Hematology During DB Phase

    Number of participants with clinically significant abnormal laboratory values in hematology included hemoglobin (Hb), hematocrit (Hct), red blood cell (RBC) count, white blood cell (WBC) count with differential, platelets, hemoglobin A1c. Here, ABL signifies abnormally low and ABH signifies abnormally high levels.

    Time frame: Up to 12 Months of DB Phase

07

Results

Posted Dec 9, 2021
Limitations and caveats
The non-inferiority design was based on the principle of enrichment; that is, criteria of clinical stability were applied prior to entry into the Double-blind Phase. Hence, the ITT (DB) analysis set does not reflect the overall sample of participants who were initially enrolled in Study PSY3015 (ClinicalTrials.gov Identifier: NCT03345342) for treatment with PP3M/PP6M. Therefore, results may not reflect true efficacy for prevention of relapses in the overall population.

Participant flow

Open-Label Phase
Participant flow — Open-Label Phase
MilestoneOpen-Label (OL) PP1M/PP3MDouble-blind PP3MDouble-blind PP6MFollow-up (FU) Phase PP3MFollow-up Phase PP6M
Started8380000
Completed7020000
Not completed1360000
Withdrew: Adverse event300000
Withdrew: Death10000
Withdrew: Initiated prohibited medication20000
Withdrew: Lack of efficacy60000
Withdrew: Lost to follow-up90000
Withdrew: Non-compliance with study drug40000
Withdrew: Physician decision40000
Withdrew: Protocol violation80000
Withdrew: Withdrawal by subject570000
Withdrew: Other150000
Double-Blind Phase
Participant flow — Double-Blind Phase
MilestoneOpen-Label (OL) PP1M/PP3MDouble-blind PP3MDouble-blind PP6MFollow-up (FU) Phase PP3MFollow-up Phase PP6M
Started022447800
Completed020241600
Not completed0226200
Withdrew: Adverse event01600
Withdrew: Death02100
Withdrew: Initiated prohibited medication00200
Withdrew: Lost to follow-up01700
Withdrew: Physician decision01400
Withdrew: Protocol violation00100
Withdrew: Withdrawal by subject0163800
Withdrew: Other01300
Follow-Up Phase
Participant flow — Follow-Up Phase
MilestoneOpen-Label (OL) PP1M/PP3MDouble-blind PP3MDouble-blind PP6MFollow-up (FU) Phase PP3MFollow-up Phase PP6M
Started00042109
Completed0003478
Not completed000831
Withdrew: Adverse event00004
Withdrew: Lost to follow-up00006
Withdrew: Physician decision00005
Withdrew: Withdrawal by subject000515
Withdrew: Other00031

Outcome measures

PrimaryTime to Relapse During the Double-Blind (DB) Phase

Time to relapse is time between participant randomization in DB Phase and first documentation of relapse event by end of Month 12 of DB phase. Relapse is defined as: a) Psychiatric hospitalization; b) Positive and Negative Syndrome Scale (PANSS) total score: Increase of 25 percentage (%), 10 point increase in PANSS for 2 analysis separated by 3-7 days if score was greater than (\>) 40, less than or equal to (\<=)40; c) Participants inflicted knowing self-injury/shown violent behavior leading to suicide, clinically significant injury to him/herself or other person/property; d) Participants had suicidal/homicidal ideation/violent behavior that was clinically significant as per investigator; e) PANSS items P1- delusions, P2- conceptual disorganization, P3-hallucinatory behavior, P6- suspiciousness/ persecution, P7-hostility, G8-uncooperativeness: score: greater than or equal to (\>=)5, \>=6 for 2 analysis separated by 3-7 days on any items if maximum score for PANSS: \<=3 or 4, respectively.

Time frame:
Up to 12 months of DB Phase
Reported as:
Median · Days
Time to Relapse During the Double-Blind (DB) Phase
DaysDB PP3MDB PP6M
Time to Relapse During the Double-Blind (DB) PhaseNA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score

The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and scores for 3 subscales: the 7-item positive-symptom (P) subscale, the 7-item negative-symptom (N) subscale, and the 16-item general-psychopathology symptom (G) subscale. Each item is rated on a scale from 1 (absent) to 7 (extreme). The PANSS total score ranges from 30 (absent disease)-210 (more severe neuropsychiatric symptoms of schizophrenia).

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scaleDB PP3MDB PP6M
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score-1.6 ± 7.40-1.8 ± 8.92
SecondaryChange From Baseline in the Clinical Global Impression - Severity (CGI-S) Score

CGI-S is defined as clinician-rated scale that assesses the severity of mental illness on a scale of 0 to 7. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to:1: normal, not at all ill; 2: borderline mentally ill; 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. A higher score implies a more severe condition.

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Mean · units on a scale
Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score
units on a scaleDB PP3MDB PP6M
Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score0.0 ± 0.630.0 ± 0.70
SecondaryChange From Baseline in the Personal and Social Performance (PSP) Scale Total Score

The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: 1) socially useful activities, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior. Each domain was assessed on a 6-point scale, from 1 (absent) to 6 (very severe) (1 = absent, 2 = mild, 3 = manifest, 4 = marked, 5 = severe, and 6 = very severe). PSP total score was calculated as sum of all the domain scores and ranges from 1 to 100. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision. Higher score indicates better performance.

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Mean · units on a scale
Change From Baseline in the Personal and Social Performance (PSP) Scale Total Score
units on a scaleDB PP3MDB PP6M
Change From Baseline in the Personal and Social Performance (PSP) Scale Total Score1.1 ± 8.111.0 ± 7.12
SecondaryPercentage of Participants With Symptomatic Remission Based on PANSS Score During DB Phase

Symptomatic remission was defined as achieving intensity level of mild or moderate on PANSS scale by all 8 items as the determinants for symptomatic remission: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, lack of spontaneity. The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent), 2 (minimal), 3 (mild), 4 (moderate), 5 (moderately severe), 6 (severe) and 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity.

Time frame:
Up to 12 months of DB Phase
Reported as:
Number · Percentage of participants
Percentage of Participants With Symptomatic Remission Based on PANSS Score During DB Phase
Percentage of participantsDB PP3MDB PP6M
Percentage of Participants With Symptomatic Remission Based on PANSS Score During DB Phase70.166.3
SecondaryChange From Baseline in the Satisfaction With Participants in Social Roles (SPSR) Score

The SPSR Short Form 8a is a participant-reported outcome used to assess the satisfaction with participation in social roles. The participants were asked to rate 8 items on 5-point Likert scale, with scores ranging from 8 to 40, where higher scores represents higher satisfaction.

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Mean · units on a scale
Change From Baseline in the Satisfaction With Participants in Social Roles (SPSR) Score
units on a scaleDB PP3MDB PP6M
Change From Baseline in the Satisfaction With Participants in Social Roles (SPSR) Score0.9 ± 7.150.6 ± 6.58
SecondaryChange From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score

TSQM-9 consists of 9 questions to assess patients' satisfaction with medication using a range of responses from 1 (extremely dissatisfied) to (7 extremely satisfied). This patient reported outcome provides scores on three parts: effectiveness, convenience, and global satisfaction. The sum of the 9-questions were calculated and used for analysis. The total score ranges from 0 to 63, with higher scores indicating better treatment satisfaction.

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Mean · units on a scale
Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score
units on a scaleDB PP3MDB PP6M
Effectiveness6.0 ± 21.183.6 ± 19.49
Convenience3.4 ± 17.761.1 ± 15.30
Overall satisfaction2.5 ± 19.290.5 ± 20.02
SecondaryChange From Baseline in the Simpson-Angus Rating Scale (SAS) Total Score

The SAS rates 10 items for general extrapyramidal symptoms (EPS) on a 5-point scale from 0 (normal) to 4 (extreme), including gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head rotation, Glabellar tap, tremor, and salivation. The SAS total score is the average score (total sum of item scores divided by the number of items) and ranges between 0 and 4. Negative change in score indicates improvement. Higher scores denote more severe condition of EPS.

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Median · units on a scale
Change From Baseline in the Simpson-Angus Rating Scale (SAS) Total Score
units on a scaleDB PP3MDB PP6M
Change From Baseline in the Simpson-Angus Rating Scale (SAS) Total Score0.00 (-0.6 to 2.1)0.00 (-0.6 to 1.5)
SecondaryNumber of Participants With Symptoms of Akathisia Assessed Using Barnes Akathisia Rating Scale (BARS) Score

BARS is used to rate observable, restless movements of drug induced akathisia and subjective awareness of restlessness and any distress associated with the akathisia. BARS consists of the following 4 items: objective assessment of akathisia symptoms, subjective assessment of the participants's awareness of inner restlessness, distress restlessness, and global clinical assessment of akathisia. First three items are rated on a 4-point scale ranging from 0 (no abnormal movements or absence of inner restlessness or no distress) to 3 (severe akathisia or awareness of intense compulsion to move most of the time or severe distress). The last item, the global clinical assessment of akathisia, is rated on a 6-point scale, ranging from 0 (no evidence of akathisia) to 5 (severe akathisia).

Time frame:
Up to 12 Months of DB Phase
Reported as:
Count of participants · Participants
Number of Participants With Symptoms of Akathisia Assessed Using Barnes Akathisia Rating Scale (BARS) Score
ParticipantsDB PP3MDB PP6M
Global Clinical Assessment185380
Objective185380
Subjective (Awareness)185380
Subjective (Distress)185380
SecondaryChange From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Total Score

AIMS is a 14-item scale. Items 1 to 8 are rated on a 5-point scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Item 9 assesses the participant's incapacitation due to abnormal movements, and item 10 assesses the participant's awareness of the abnormal movements and associated distress. Items 9 and 10 are rated on 5-point scales ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Items 11 to 14 are yes/no questions regarding the global judgement and dental status of the participant. The total score is the sum of the scores for the 14 items and the possible total score ranges from 0 to 44. A higher total score is indicative of more severe dyskinetic movements.

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Median · units on a scale
Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Total Score
units on a scaleDouble-blind (DB) PP3MDouble-blind (DB) PP6M
Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Total Score0.0 (-3 to 2)0.0 (-7 to 14)
SecondaryNumber of Participants Based on Columbia Suicide Severity Rating Scale (C-SSRS) Total Score

The C-SSRS is a questionnaire used for suicide risk assessment. Affirmative or negative responses are provided to items 1 to 5 for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods \[not plan\] without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and items 6 to 10 for suicide behavior (6. Preparatory acts or behavior, 7. Aborted attempt, 8. Interrupted attempt, 9. Actual attempt, 10. Completed suicide). Total score ranges from 1 to 10. Higher scores indicate more severe suicidal ideation.

Time frame:
Baseline and endpoint (12 Months of DB Phase)
Reported as:
Count of participants · Participants
Number of Participants Based on Columbia Suicide Severity Rating Scale (C-SSRS) Total Score
ParticipantsDB PP3MDB PP6M
Baseline (0= No event)221477
Baseline (1= Wish to be dead)30
Baseline (2= Non-specific suicidal thought)01
Baseline (3= Suicidal ideation-no intent)00
Baseline (4= Ideation with intent, no plan)00
Baseline (5= Ideation with plan/intent)00
Baseline (6= Preparatory acts/behavior)00
Baseline (7= Aborted attempt)00
Baseline (8= Interrupted attempt)00
Baseline (9= Actual attempt)00
Baseline (10= Suicide)00
End Point (0= No event)218471
End Point (1= Wish to be dead)11
End Point (2= Non-specific suicidal thought)00
End Point (3= Suicidal ideation-no intent)01
End Point (4= Ideation with intent, no plan)10
End Point (5= Ideation with plan/intent)12
End Point (6= Preparatory acts/behavior)00
End Point (7= Aborted attempt)00
End Point (8= Interrupted attempt)00
End Point (9= Actual attempt)01
End Point (10= Suicide)00
SecondaryNumber of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values During DB Phase

Number of participants with treatment-emergent abnormal ECG values were reported. It includes heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute (bpm) , abnormally high refers greater than or equal to \[\>=\] 100 bpm), pulse rate (PR) interval (abnormally high refers to \>= 210 milliseconds \[msec\]), QRS interval (abnormally Low refers to \<= 50, abnormally high refers to \>= 120 msec) and QT interval (abnormally low refers to \<= 200, abnormally high \>= 500 msec).

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values During DB Phase
ParticipantsDB PP3MDB PP6M
Heart Rate value <=5059
Heart Rate value >=1002036
PR Duration value >= 21038
QRS Duration value <= 5000
QRS Duration value >= 12012
QT Duration value <= 20000
QT Duration value >= 50000
SecondaryChange From Baseline in the Body Mass Index (BMI) During DB Phase

Change from baseline in BMI was reported.

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Mean · kilogram per meter square (kg/m^2)
Change From Baseline in the Body Mass Index (BMI) During DB Phase
kilogram per meter square (kg/m^2)DB PP3MDB PP6M
Change From Baseline in the Body Mass Index (BMI) During DB Phase0.3 ± 1.780.0 ± 1.72
SecondaryChange From Baseline in the Waist Circumference During DB Phase

Change from baseline in waist circumference was reported.

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Mean · centimeter (cm)
Change From Baseline in the Waist Circumference During DB Phase
centimeter (cm)DB PP3MDB PP6M
Change From Baseline in the Waist Circumference During DB Phase0.82 ± 5.1370.37 ± 5.157
SecondaryChange From Baseline in the Body Weight During DB Phase

Change from baseline in body weight was reported.

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Mean · kilogram (kg)
Change From Baseline in the Body Weight During DB Phase
kilogram (kg)DB PP3MDB PP6M
Change From Baseline in the Body Weight During DB Phase0.96 ± 5.1030.10 ± 4.959
SecondaryChange From Baseline in the Vital Signs (Pulse Rate) During DB Phase

Change from baseline vital signs (pulse rate) were reported. This included supine pulse rate, standing pulse rate and supine-standing pulse rate.

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in the Vital Signs (Pulse Rate) During DB Phase
beats per minute (bpm)Double-blind (DB) PP3MDouble-blind (DB) PP6M
Supine Pulse Rate1.2 ± 11.570.6 ± 11.56
Standing Pulse Rate2.6 ± 12.280.9 ± 12.60
Pulse Rate (Standing-Supine)1.5 ± 8.850.2 ± 8.31
SecondaryChange From Baseline in the Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) During DB Phase

Change from baseline in vital signs including SBP and DBP (supine/standing) were reported.

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Mean · millimetre of mercury (mmHg)
Change From Baseline in the Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) During DB Phase
millimetre of mercury (mmHg)Double-blind (DB) PP3MDouble-blind (DB) PP6M
Supine SBP-0.3 ± 13.140.6 ± 9.96
Standing SBP0.8 ± 12.081.3 ± 10.40
SBP (Standing-Supine)1.0 ± 9.830.6 ± 7.32
Supine DBP0.1 ± 9.25-0.4 ± 7.49
Standing DBP0.3 ± 9.390.4 ± 7.48
DBP (Standing-Supine)0.2 ± 7.790.7 ± 6.43
SecondaryChange From Baseline in Positive and Syndrome Scale (PANSS) Subscales Score During DB Phase

The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).

Time frame:
Baseline (DB) to 12 Months of DB Phase
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Syndrome Scale (PANSS) Subscales Score During DB Phase
units on a scaleDB PP3MDB PP6M
Positive Subscale Score-0.1 ± 2.82-0.1 ± 3.30
Negative Subscale Score-0.6 ± 2.61-0.7 ± 2.70
General Psychopathology Subscale Score-0.9 ± 4.18-1.0 ± 4.86
SecondaryNumber of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Chemistry During DB Phase

Number of participants with clinically significant abnormal laboratory values in chemistry included alanine aminotransferase (Unit per Litre \[U/L\]), albumin (Gram per Litre \[g/L\]), alkaline phosphatase (U/L), aspartate aminotransferase (U/L), bicarbonate (millimoles per litre \[mmol/L\]), bilirubin (micromoles per litre \[umol/L\]), calcium (mmol/L), chloride (mmol/L), cholesterol (mmol/L), creatinine (umol/L), gamma glutamyl transferase (GGT) (U/L), glucose (mmol/L), high-density lipoproteins (HDL) cholesterol (mmol/L), low density lipoproteins (LDL) cholesterol (mmol/L), lactate dehydrogenase (U/L), phosphate (mmol/L), potassium (mmol/L), protein (mmol/L), sodium (mmol/L), triglycerides (mmol/L), urate (umol/L), urea nitrogen (mmol/L) were reported. Here, ABL signifies abnormally low and ABH signifies abnormally high levels.

Time frame:
Up to 12 Months of DB Phase
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Chemistry During DB Phase
ParticipantsDB PP3MDB PP6M
Alanine Aminotransferase ABH01
Albumin ABL00
Albumin ABH00
Alkaline Phosphatase ABH00
Aspartate Aminotransferase ABH00
Bicarbonate ABL03
Bicarbonate ABH00
Bilirubin ABH01
Calcium ABL00
Calcium ABH00
Chloride ABL45
Chloride ABH00
Cholesterol ABH24
Creatinine ABH00
Gamma Glutamyl Transferase ABH02
Glucose ABL10
Glucose ABH15
HDL Cholesterol ABL1840
LDL Cholesterol ABL3344
LDL Cholesterol ABH922
Lactate Dehydrogenase ABH01
Phosphate ABL18
Phosphate ABH00
Potassium ABL00
Potassium ABH00
Protein ABL01
Sodium ABL10
Sodium ABH00
Triglycerides ABH46
Urate ABL00
Urate ABH14
Urea Nitrogen ABH00
SecondaryNumber of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Hematology During DB Phase

Number of participants with clinically significant abnormal laboratory values in hematology included hemoglobin (Hb), hematocrit (Hct), red blood cell (RBC) count, white blood cell (WBC) count with differential, platelets, hemoglobin A1c. Here, ABL signifies abnormally low and ABH signifies abnormally high levels.

Time frame:
Up to 12 Months of DB Phase
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Hematology During DB Phase
ParticipantsDB PP3MDB PP6M
Basophils ABL00
Eosinophils ABL11
Erythrocytes ABL10
Erythrocytes ABH00
Hematocrit ABL01
Hematocrit ABH00
Hemoglobin ABL10
Hemoglobin ABH00
Leukocytes ABL00
Leukocytes ABH24
Lymphocytes ABL02
Lymphocytes ABH11
Monocytes ABH00
Neutrophils ABL10
Neutrophils ABH00
Platelets ABL00
Platelets ABH00

Adverse events

Collected over Up to 2.5 Years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-Label (OL) PP1M/PP3M1/838 (0.1%)23/838 (2.7%)127/838 (15.2%)
Double-blind PP3M2/224 (0.9%)15/224 (6.7%)52/224 (23.2%)
Double-blind PP6M1/478 (0.2%)24/478 (5%)125/478 (26.2%)
Follow-up (FU) Phase PP3M0/42 (0%)1/42 (2.4%)1/42 (2.4%)
Follow-up Phase PP6M0/109 (0%)6/109 (5.5%)5/109 (4.6%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventOpen-Label (OL) PP1M/PP3MDouble-blind PP3MDouble-blind PP6MFollow-up (FU) Phase PP3MFollow-up Phase PP6M
Suicidal IdeationPsychiatric disorders3/8382/2241/4781/420/109
SchizophreniaPsychiatric disorders6/8381/2248/4780/422/109
Brain NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/8380/2240/4780/421/109
Nasal Sinus CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/8380/2240/4780/421/109
Mental DisorderPsychiatric disorders0/8380/2240/4780/421/109
Suicide AttemptPsychiatric disorders2/8380/2242/4780/421/109
Psychotic DisorderPsychiatric disorders3/8382/2241/4780/420/109
Sudden DeathGeneral disorders0/8381/2240/4780/420/109
CholelithiasisHepatobiliary disorders0/8381/2240/4780/420/109
Femur FractureInjury, poisoning and procedural complications0/8381/2240/4780/420/109
Most frequent other events
Most frequent other events
EventOpen-Label (OL) PP1M/PP3MDouble-blind PP3MDouble-blind PP6MFollow-up (FU) Phase PP3MFollow-up Phase PP6M
Injection Site PainGeneral disorders72/8389/22437/4780/420/109
Weight IncreasedInvestigations8/83817/22440/4780/420/109
HeadacheNervous system disorders16/83812/22432/4780/420/109
NasopharyngitisInfections and infestations22/83813/22422/4781/424/109
Upper Respiratory Tract InfectionInfections and infestations19/8389/22424/4780/421/109

Baseline characteristics

Age, Continuous
Age, Continuous(years)Open-Label (OL) PP1M/PP3M
Mean40.8 ± 11.68
Sex: Female, Male
Sex: Female, Male(Participants)Open-Label (OL) PP1M/PP3M
Female285
Male553
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Open-Label (OL) PP1M/PP3M
Hispanic or Latino118
Not Hispanic or Latino710
Unknown or Not Reported10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open-Label (OL) PP1M/PP3M
American Indian or Alaska Native1
Asian111
Native Hawaiian or Other Pacific Islander3
Black or African American106
White606
More than one race5
Unknown or Not Reported6
Region of Enrollment
Region of Enrollment(Participants)Open-Label (OL) PP1M/PP3M
ARGENTINA55
AUSTRALIA4
BRAZIL90
BULGARIA46
CZECH REPUBLIC45
FRANCE7
HONG KONG4
HUNGARY20
INDIA42
ITALY8
KOREA, REPUBLIC OF4
MALAYSIA22
MEXICO23
POLAND68
RUSSIAN FEDERATION139
SPAIN29
TAIWAN31
TURKEY26
UKRAINE50
UNITED STATES125
08

Study locations

138 sites
  • Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • California Pharmaceutical Research Institute, Inc.
    Anaheim, California 92804, United States
  • ATP Clinical Research
    Costa Mesa, California 92626, United States
  • Collaborative NeuroScience Network
    Garden Grove, California 92845, United States
  • Synergy East
    Lemon Grove, California 91945, United States
  • Pacific Research Partners
    Oakland, California 94607, United States
  • SF-Care, Inc
    San Rafael, California 94901, United States
  • New Life Medical Research Center, Inc.
    Hialeah, Florida 33012, United States
  • Clintex Research Group
    Miami, Florida 33135, United States
  • Florida Research Center Inc.
    Miami, Florida 33174, United States
  • Olympian Clinical Research
    Tampa, Florida 33614, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • Alexian Behavioral Health Hospital
    Hoffman Estates, Illinois 60169, United States
  • Ascension via Christi Research
    Wichita, Kansas 67214, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Cherry Street Services, Inc.
    Grand Rapids, Michigan 49503, United States
  • St. Louis Clinical Trials
    Saint Louis, Missouri 63141, United States
  • The Zucker Hillside Hospital
    Glen Oaks, New York 11004, United States
  • Clinical Trials of America Inc
    Hickory, North Carolina 28601, United States
  • Wexner Medical Center at the Ohio State University
    Columbus, Ohio 43210, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • University of Pennsylvania Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Future Search Trials of Dallas
    Dallas, Texas 75231, United States
  • Psychiatric and Behavioral Solutions
    Salt Lake City, Utah 84105-2425, United States
  • Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales
    Ciudad Autónoma De Buenos Aires, C1133AAH, Argentina
  • CEN
    Cordoba, X5004FJF, Argentina
  • Sanatorio Prof. Leon S. Morra
    Cordoba, X5009BIN, Argentina
  • Instituto de Neurociencias San Agustin
    La Plata, 1900, Argentina
  • Clinica Privada de Salud Mental Santa Teresa de Ávila
    La Plata, B1904ADM, Argentina
  • C I A P Centro de investigacion y Asistencia en Psiquiatria
    Rosario, 2000, Argentina
  • The Lyell McEwin Hospital
    Elizabeth Vale, 5112, Australia
  • Neuro Trials Victoria
    Noble Park, 3174, Australia
  • Trial Tech Tecnologia em Pesquisas com Medicamentos
    Curitiba, 80240-280, Brazil
  • Instituto Bairral de Psiquiatria
    Itapira, 13970-905, Brazil
  • Hospital das Clinicas de Porto Alegre
    Porto Alegre, 90035-903, Brazil
  • Ruschel Medicina e Pesquisa Clínica Ltda
    Rio de Janeiro, 22270 060, Brazil
  • SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo
    Sao Paulo, 04020-060, Brazil
  • CPQuali Pesquisa Clinica LTDA ME
    São Paulo, 01228-900, Brazil
  • Hospital Das Clinicas Da Faculdade De Medicina Da USP
    São Paulo, 05403-903, Brazil
  • Mental Health Center Prof. Dr. Ivan Temkov
    Bourgas, 8001, Bulgaria
  • State Psychiatric Hospital Pazardzhik
    Pazardzhik, 4400, Bulgaria
  • UMHAT 'Sveti Georgi'-Plovdiv
    Plovdiv, 4002, Bulgaria
  • State Psychiatric HospitalDr.Georgi Kissiov
    Radnevo, 6260, Bulgaria
  • Centre for Mental Health Prof.N.Shipkovenski EOOD
    Sofia, 1377, Bulgaria
  • Medical Center Intermedica, OOD
    Sofia, 1680, Bulgaria
  • Psychiatricka ambulance, MUDr. Marta Holanova
    Brno, 61500, Czechia
  • NeuropsychiatrieHK, s.r.o.
    Hradec Kralove-Vekose, 50341, Czechia
  • A Shine S R O
    Plzen, 31200, Czechia
  • Institut Neuropsychiatricke pece
    Prague, 18600, Czechia
  • Psychiatricka ambulance MUDr. Simona Papezova
    Prague, 19000, Czechia
  • Pragtis S R O
    Praha 2, 12000, Czechia
  • C.H.S. Charles Perrens
    Bordeaux, 33076, France
  • CHRU La Colombière
    Montpellier, 34090, France
  • CHU Caremeau
    Nimes Cedex 9, 30029, France
  • Hopital Sainte Anne
    Paris, 75674, France
  • Hopital Sainte Musse
    Toulon Cedex, 83000, France
  • Kwai Chung Hospital
    Hong Kong, Hong Kong
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Józsefvarosi Szent Kozma Egészségügyi Központ
    Budapest, 1084, Hungary
  • Petz Aladar Megyei Oktato Korhaz
    Gyor, 9023, Hungary
  • Bács-Kiskun Megyei Kórház a Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza
    Kalocsa, 6300, Hungary
  • CRU Hungary Kft.
    Miskolc, 3529, Hungary
  • Ratandeep Multispeciality Hospital
    Ahmedabad, 380008, India
  • Sri Ramachandra Medical Centre
    Chennai, 600116, India
  • Asha hospital
    Hyderabad, 500034, India
  • Ahana Hospitals
    Madurai, 625020, India
  • Vinaya Hospital and Research Center
    Mangalore, 575003, India
  • Kasturba Medical College Hospital
    Manipal, 576104, India
  • Jehangir Clinical Development Center Pvt Ltd
    Pune, 411001, India
  • Deva Institute of Health Care and Research Pvt Ltd
    Varanasi, 221005, India
  • Clinica Psichiatrica - Università di Cagliari
    Cagliari, 09127, Italy
  • Dipartimento di Salute Mentale
    Lecce, 73100, Italy
  • Seconda Universita degli Studi di Napoli - Azienda Ospedaliera Universitaria
    Napoli, 80138, Italy
  • Universita degli Studi di Roma 'La Sapienza' - Azienda Ospedaliera Sant Andrea
    Roma, 00189, Italy
  • Chonnam National University Hospital
    Gwangju, 61469, Korea, Republic of
  • CHA Bundang Medical Center, CHA University
    Gyeonggi-do, 13496, Korea, Republic of
  • Chonbuk National Univ Hospital
    Jeonju, 54907, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Hospital Bahagia Ulu Kinta
    Ipoh, 31250, Malaysia
  • Hospital Kuala Lumpur
    Kuala Lumpur, 50586, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Sarawak General Hospital
    Kuching, 93586, Malaysia
  • Gabipros SC
    Mexico City, 07810, Mexico
  • Instituto Neuropsique
    Monterrey, 64610, Mexico
  • Centro de Estudios Clinicos y Especialidades Medicas S C
    Monterrey, 64620, Mexico
  • Infosame/Research
    Monterrey, 64710, Mexico
  • Centro de Atencion e Investigacion Cardiovascular del Potosi S C
    San Luis Potosí, 78200, Mexico
  • Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk
    Bialystok, 15-404, Poland
  • Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski
    Bialystok, 15-464, Poland
  • Zespol Opieki Zdrowotnej w Chelmnie
    Chelmno, 86-200, Poland
  • Centrum Badan Klinicznych PI House sp z o o
    Gdansk, 80 546, Poland
  • Szpital Specjalistyczny im H Klimontowicza Oddzial Psychiatryczny
    Gorlice, 38-300, Poland
  • Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
    Leszno, 64-100, Poland
  • Centrum Medyczne Luxmed Sp z o o
    Lublin, 20 109, Poland
  • Poradnia Zdrowia Psychicznego 'Syntonia' w Pruszczu Gdanskim
    Pruszcz Gdanski, 83-000, Poland
  • Mazowieckie Specjalistyczne Centrum Zdrowia im. Prof. Jana Mazurkiewicza w Pruszkowie
    Pruszkow, 05-802, Poland
  • Wojewodzki Szpital Zespolony im L Rydygiera w Toruniu
    Torun, 87 100, Poland
  • Sverdlovsk Regional Clinical Psychiatric Hospital
    Ekaterinburg, Russian Federation
  • Clinical Psychiatric Hospital #3 Named After V.A. Gilyarovsky
    Moscow, 107076, Russian Federation

Showing the first 100 of 138 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, Cohen K, Schotte A, Milz R, Venkatasubramanian R, T'Jollyn H, Walling DP, Galderisi S, Gopal S. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):238-251. doi: 10.1093/ijnp/pyab071. PubMed 34791283 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in May 2020, 29 months.

Results were first posted in Dec 2021, 1 year 7 months after primary completion. A results delay was requested in May 2021.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 29 months is close to that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2017
First posted
Nov 17, 2017
StartActual
Nov 20, 2017
Primary completionActual
May 8, 2020
CompletionActual
May 8, 2020
Results delay requested
May 5, 2021
Results first posted
Dec 9, 2021
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03345342
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Nov 20, 2017
Primary completion
May 8, 2020
Completion
May 8, 2020
Results posted
Dec 9, 2021
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion